

ASX: CVB

4 December 2023

Securities released from escrow

CurveBeam AI Limited (ASX:CVB) (the **Company**) hereby advises pursuant to ASX Listing Rule 3.10A that the following securities were due to be released from ASX restrictions on the dates outlined below:

Date	Shares	Noteholder Options
31 October 2023	8,433,924	4,685,495
10 November 2023	11,447,794	-

Of these securities, only 13,132,177 shares and 1,123,991 noteholder options have become free from all escrow; the balance remains subject to ongoing voluntary escrow.

The Company notes the lodgement of this notice outside of the time prescribed by the ASX Listing Rules. The late lodgement was due to an administrative oversight. The administrative oversight has not affected the Company's current arrangement for ensuring timely notification in accordance with the ASX Listing Rules.

Release approved by the Company Secretary.

About CurveBeam AI Limited

CurveBeam AI Limited (ABN 32 140 706 618) (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

CEO and Managing Director:

Greg Brown
info@curvebeamai.com

Investor / media enquiries contact:

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au